Finance

Lists
Outlook: 66.7% bullish·1.8% bearish
Go to analysis
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
US$746,54
+0,94%
(+6,97) 1D
US$745,55
-0,13% (-0,99)
After hours
Closed: 9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
US$737,20
High
US$751,27
Low
US$732,83
Mkt. cap
76,86 ຕື້
Avg. vol.
720,68 ພັນ
Volume
466,03 ພັນ
Dividend
0,50%
Quarterly dividend
US$0,94
Ex-dividend date
18 ສ.ຫ. 2026
P/E ratio
18,46
52-wk high
US$859,34
52-wk low
US$541,00
EPS
US$40,45
Beta
0,16
Shares outstanding
101,14 ລ້ານ
No. of employees
15 ພັນ
Open
US$737,20
High
US$751,27
Low
US$732,83
Mkt. cap
76,86 ຕື້
Avg. vol.
720,68 ພັນ
Volume
466,03 ພັນ
Dividend
0,50%
Quarterly dividend
US$0,94
Ex-dividend date
18 ສ.ຫ. 2026
P/E ratio
18,46
52-wk high
US$859,34
52-wk low
US$541,00
EPS
US$40,45
Beta
0,16
Shares outstanding
101,14 ລ້ານ
No. of employees
15 ພັນ
News stories
From web sources and news partners
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15,3 ພັນ
Founded1988
HeadquartersTarrytown, ລັດນີວຢອກ, ສະຫະລັດ
SectorBiotechnology
Websiteregeneron.com
Analyst ratings
Based on 22 analysts giving stock ratings to REGN in the past 3 months
Buy
Buy
14
Hold
8
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for REGN in the last 3 months.
Highest
Current US$746,54
US$1.030,00 (+37,97%)
Average
US$857,62 (+14,88%)
Lowest
US$740,00 (-0,88%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Hold
Maintained
US$810,00
+8,5%
10/08/2026
Gregory Renza
Truist Financial
Buy
Maintained
US$780,00
+4,5%
10/07/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
US$779,00
+4,3%
10/07/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
US$950,00
+27,3%
10/06/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
US$761,00
+1,9%
10/02/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
US$972,00
+30,2%
10/01/2026
David Risinger
Leerink Partners
Hold
Maintained
-
-
10/02/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$854,00
+14,4%
10/02/2026
Louise Chen
Scotiabank
Hold
Maintained
US$770,00
+3,1%
10/02/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
US$891,00
+19,4%
10/01/2026
Eliana Merle
Barclays
Buy
Maintained
US$917,00
+22,8%
10/02/2026
Geoff Meacham
Citi
Hold
Maintained
US$740,00
-0,9%
10/02/2026
Akash Tewari
Jefferies
Buy
Maintained
US$930,00
+24,6%
10/01/2026
Evan Seigerman
BMO Capital
Buy
Maintained
US$920,00
+23,2%
10/01/2026
Jasper Hellweg
Argus Research
Buy
Upgraded
US$850,00
+13,9%
09/30/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
US$750,00
+0,5%
09/28/2026
Eve Burstein
Bernstein
Hold
Maintained
US$756,00
+1,3%
09/25/2026
Rajesh Kumar
HSBC
Buy
Maintained
US$920,00
+23,2%
09/10/2026
Yatin Suneja
Guggenheim
Buy
Maintained
US$1.030,00
+38%
08/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
US$795,00
+6,5%
07/30/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
US$960,00
+28,6%
07/30/2026
John Newman
Canaccord Genuity
Buy
Maintained
US$875,00
+17,2%
07/22/2026
Alexandria Hammond
Wolfe Research
Buy
Reiterated
US$860,00
+15,2%
05/18/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
US$825,00
+10,5%
05/18/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
US$960,00
+28,6%
05/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$865,00
+15,9%
04/30/2026
William Pickering
Bernstein
Buy
Maintained
US$921,00
+23,4%
04/08/2026
Christopher Raymond
Raymond James
Buy
Maintained
US$870,00
+16,5%
01/30/2026
Last report
30 ກ.ລ. 2026
Fiscal period
Q2 2026
US$14,29 / US$10,21
+39,99%beat
Revenue / Est. (USD)
4,29 ຕື້ / 3,82 ຕື້
+12,22%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
3,75 ຕື້
3,88 ຕື້
3,61 ຕື້
4,29 ຕື້
Cost of goods sold
2,00 ຕື້
2,21 ຕື້
2,21 ຕື້
2,21 ຕື້
Cost of revenue
2,00 ຕື້
2,21 ຕື້
2,21 ຕື້
2,21 ຕື້
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
657,80 ລ້ານ
775,00 ລ້ານ
647,70 ລ້ານ
662,10 ລ້ານ
Operating expense
647,80 ລ້ານ
775,00 ລ້ານ
647,70 ລ້ານ
662,10 ລ້ານ
Total operating expenses
2,64 ຕື້
2,99 ຕື້
2,86 ຕື້
2,87 ຕື້
Operating income
1,11 ຕື້
898,60 ລ້ານ
744,80 ລ້ານ
1,42 ຕື້
Other non operating income
3,00 ລ້ານ
958,50 ລ້ານ
-7,30 ລ້ານ
100,00 ພັນ
EBT including unusual items
1,76 ຕື້
1,04 ຕື້
831,20 ລ້ານ
1,53 ຕື້
EBT excluding unusual items
1,27 ຕື້
2,04 ຕື້
908,10 ລ້ານ
1,59 ຕື້
Income tax expense
303,30 ລ້ານ
199,10 ລ້ານ
104,00 ລ້ານ
230,90 ລ້ານ
Effective tax rate
17,20%
19,08%
12,51%
15,11%
Other operating expenses
-10,00 ລ້ານ
-
-
-
Net income
1,46 ຕື້
844,60 ລ້ານ
727,20 ລ້ານ
1,30 ຕື້
Net profit margin
38,89%
21,74%
20,17%
30,23%
Earnings per share
11,83
11,44
9,47
14,29
Interest and investment income
175,10 ລ້ານ
193,30 ລ້ານ
183,50 ລ້ານ
183,30 ລ້ານ
Interest expense
-19,30 ລ້ານ
-12,20 ລ້ານ
-12,90 ລ້ານ
-11,00 ລ້ານ
Net interest expenses
155,80 ລ້ານ
181,10 ລ້ານ
170,60 ລ້ານ
172,30 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
1,25 ຕື້
1,04 ຕື້
868,00 ລ້ານ
1,54 ຕື້
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google